Division of Endocrinology and Metabolism, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
Division of Neurology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
Can J Diabetes. 2015 Oct;39(5):390-7. doi: 10.1016/j.jcjd.2015.02.006. Epub 2015 Apr 28.
In vivo corneal confocal microscopy (IVCCM) has been established in cross-sectional studies as a valid measure for the identification of diabetic sensorimotor polyneuropathy (DSP). We aimed to determine the predictive validity of a baseline IVCCM measure in identifying future DSP onset in patients with type 1 diabetes.
We followed 65 patients with type 1 diabetes without DSP at baseline. They were followed longitudinally for a mean of 3.5±0.9 years and underwent IVCCM, clinical and electrophysiologic examinations at baseline and follow up. At the end of follow up, participants were assigned as new-onset cases of DSP or as controls. Predictive validity was assessed using receiver operating characteristic curves.
At baseline, participants were 34±15 years of age with mean diabetes duration of 18±12 years. The 11 (17%) new-onset cases of DSP were similar to the 54 (83%) controls in baseline age, diabetes duration, gender, glycated hemoglobin levels and electrophysiologic parameters (p≥0.20). However, cases of new onset had significantly lower baseline corneal nerve fibre length (CNFL) and branch density (p<0.05). For identification of new-onset cases, area under the receiver operating characteristic curve for CNFL was 0.78 with an optimal threshold of 14.9 mm/mm(2) (sensitivity=0.82, specificity=0.69).
Despite similar clinical and electrophysiologic parameters, participants with type 1 diabetes at risk for future DSP had significantly lower baseline IVCCM measures. CNFL may have applicability in identifying high-risk patients for therapeutic intervention in clinical research and practice.
在横断面研究中,活体共聚焦角膜显微镜(IVCCM)已被确立为识别糖尿病感觉运动性多神经病(DSP)的有效方法。我们旨在确定基线 IVCCM 测量值在识别 1 型糖尿病患者未来 DSP 发病中的预测有效性。
我们对 65 名基线时无 DSP 的 1 型糖尿病患者进行了随访。他们平均随访 3.5±0.9 年,并在基线和随访时接受了 IVCCM、临床和电生理检查。随访结束时,根据是否发生新的 DSP 将参与者分为新发病例或对照组。使用受试者工作特征曲线评估预测有效性。
基线时,参与者年龄为 34±15 岁,平均糖尿病病程为 18±12 年。11 例(17%)新发 DSP 病例与 54 例(83%)对照组在基线年龄、糖尿病病程、性别、糖化血红蛋白水平和电生理参数方面相似(p≥0.20)。然而,新发病例的角膜神经纤维长度(CNFL)和分支密度明显较低(p<0.05)。对于识别新发病例,CNFL 的受试者工作特征曲线下面积为 0.78,最佳阈值为 14.9mm/mm²(灵敏度=0.82,特异性=0.69)。
尽管临床和电生理参数相似,但未来有发生 DSP 风险的 1 型糖尿病患者的基线 IVCCM 测量值明显较低。CNFL 可能适用于识别高危患者,以便在临床研究和实践中进行治疗干预。